As per the agreement, Alexion will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of LogicBio for $2.07 per share, a rare 660% premium on LogicBio’s share price.

I n a notable market movement, shares of LogicBio Therapeutics, Inc. (LOGC) reached a 52-week high, trading at $8.24, marking a significant milestone after posting impressive gains of nearly 49% ...

His experience also includes M&A and corporate development at LogicBio Therapeutics ... creating a robust pipeline targeting CNS, neuromuscular and eye diseases. Headquartered in Paris, France ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...